Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 22;14(11):569.
doi: 10.3390/metabo14110569.

Species Differences in Ezetimibe Glucuronidation

Affiliations

Species Differences in Ezetimibe Glucuronidation

Shalom Emmanuel et al. Metabolites. .

Abstract

Background: Peclinical and clinical studies have revealed that ezetimibe, an approved cholesterol-absorption inhibitor, is rapidly and extensively metabolized to a more potent metabolite, ezetimibe glucuronide. Since different species are commonly used in the pharmacokinetic and pharmacodynamic studies of ezetimibe, it is essential to determine the species difference in glucuronidation of ezetimibe in order to accurately evaluate ezetimibe's pharmacokinetics and pharmacodynamics. The purpose of the study was to compare species differences in ezetimibe glucuronidation rates using intestinal microsomes from humans, rats, mice, monkeys, and dogs.

Method: Intestinal microsomes from different species were used to assess the ezetimibe glucuronidation rates. Multiple substrate concentrations at 0.5, 2, 5, 10, 20, 30, 40, and 50 µM were tested and fitted into the Michaelis-Menten model to determine the enzyme kinetic parameters.

Results: The results showed that the glucuronidation rates with these tested species were significantly different. Kinetic studies revealed that the maximum metabolic rate (Vmax) was higher in monkeys (3.87 ± 0.22 nmol/mg/min) than that in rat (2.40 ± 0.148 nmol/mg/min) and mouse (2.23 ± 0.10 nmol/mg/min), and then human (1.90 ± 0.08 nmol/mg/min) and dog (1.19 ± 0.06 nmol/mg/min). The CLint was an 8.17-fold difference among these species, following the order of mouse > dog > human > rat = monkey.

Conclusions: The study revealed that the rate of ezetimibe glucuronidation in the intestine was different in different species and has an impact on ezetimibe glucuronidation in the intestine. When analyzing the pharmacodynamics, pharmacokinetics, or toxicology of ezetimibe using different models, these species differences must be taken into consideration.

Keywords: UGT; ezetimibe; glucuronidation; species differences.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Chemical structures, a representative UPLC chromatogram, and UV spectra of ezetimibe and ezetimibe glucuronide (Eze-G). (A), Chemical structures of ezetimibe and its glucuronide and glucuronidation reaction; (B), UV spectra of the additional peak and ezetimibe-glucuronide; (C), A Representative Chromatogram of the analytes with I.S.
Figure 2
Figure 2
Ezetimibe glucuronidation in intestinal microsomes of mouse, rat, dog, monkey, and human. The substrate concentration is 5 μM, and the incubation is 1 h. The results show that the metabolic rate of dog intestinal microsomes is significantly lower than that of the other species (* p < 0.05, one-way ANOVA).
Figure 3
Figure 3
Kinetic study of Ezetimibe glucuronidation in intestinal microsomes of various species: (A) human, (B) rat, (C) monkey, (D) mouse, and (E) dog. The results showed that the Vmax of rat live microsomes is significantly lower than the others.

References

    1. Boutari C., Karagiannis A., Athyros V.G. Rosuvastatin and ezetimibe for the treatment of dyslipidemia and hypercholesterolemia. Expert Rev. Cardiovasc. Ther. 2021;19:575–580. doi: 10.1080/14779072.2021.1940959. - DOI - PubMed
    1. Yu M., Liang C., Kong Q., Wang Y., Li M. Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: A meta-analysis of literature. Lipids Health Dis. 2020;19:1. doi: 10.1186/s12944-019-1182-5. - DOI - PMC - PubMed
    1. Popovic D.S., Papachristou S., Stokic E., Papanas N. Ezetimibe and Insulin Resistance. Curr. Vasc. Pharmacol. 2022;20:315–317. doi: 10.2174/1570161120666220301140528. - DOI - PubMed
    1. Mercep I., Strikic D., Sliskovic A.M., Reiner Z. New Therapeutic Approaches in Treatment of Dyslipidaemia—A Narrative Review. Pharmaceuticals. 2022;15:839. doi: 10.3390/ph15070839. - DOI - PMC - PubMed
    1. Ghosal A., Hapangama N., Yuan Y., Achanfuo-Yeboah J., Iannucci R., Chowdhury S., Alton K., Patrick J.E., Zbaida S. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia) Drug Metab. Dispos. 2004;32:314–320. doi: 10.1124/dmd.32.3.314. - DOI - PubMed

LinkOut - more resources